c-MET (F1200I)

MET · Variant type: point · HGVS: p.F1200I

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Crizotinib	92.2%	7.8%	91.39
2	Gilteritinib	92.0%	8.0%	88.97
3	Tepotinib	83.3%	16.7%	99.75
4	Tivozanib	82.5%	17.5%	92.42
5	Capmatinib	81.1%	18.9%	99.75
6	Lenvatinib	73.0%	27.0%	97.74
7	Pacritinib	72.1%	27.9%	88.64
8	Cabozantinib	70.4%	29.6%	92.73
9	Repotrectinib	64.9%	35.1%	84.21
10	Vemurafenib	58.6%	41.4%	96.49
11	Defactinib	55.4%	44.6%	92.68
12	Selpercatinib	44.1%	55.9%	96.72
13	Sunitinib	41.8%	58.2%	91.73
14	Fostamatinib	38.2%	61.8%	96.74
15	Fedratinib	30.5%	69.5%	96.21
16	Axitinib	26.6%	73.4%	93.23
17	Neratinib	26.0%	74.0%	93.18
18	Brigatinib	25.4%	74.6%	82.96
19	Deucravacitinib	21.6%	78.4%	98.99
20	Entrectinib	21.1%	78.9%	93.69
21	Canertinib	15.7%	84.3%	96.49
22	Darovasertib	13.3%	86.7%	96.99
23	Ponatinib	13.1%	86.9%	78.23
24	Vandetanib	12.2%	87.8%	95.74
25	Abemaciclib	11.1%	88.9%	91.48

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Crizotinib	92.2%	—	—
Gilteritinib	92.0%	—	—
Tepotinib	83.3%	—	—
Tivozanib	82.5%	—	—
Capmatinib	81.1%	—	—
Lenvatinib	73.0%	—	—
Pacritinib	72.1%	—	—
Cabozantinib	70.4%	—	—
Repotrectinib	64.9%	—	—
Vemurafenib	58.6%	—	—
Defactinib	55.4%	—	—
Selpercatinib	44.1%	—	—
Sunitinib	41.8%	—	—
Fostamatinib	38.2%	—	—
Fedratinib	30.5%	—	—
Axitinib	26.6%	—	—
Neratinib	26.0%	—	—
Brigatinib	25.4%	—	—
Deucravacitinib	21.6%	—	—
Entrectinib	21.1%	—	—
Canertinib	15.7%	—	—
Darovasertib	13.3%	—	—
Ponatinib	13.1%	—	—
Vandetanib	12.2%	—	—
Abemaciclib	11.1%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 17.6ms